Current and historical daily PE Ratio for Regeneron Pharmaceuticals Inc (
BSP:REGN34
) from 2019 to Apr 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Regeneron Pharmaceuticals stock (BSP:REGN34) PE ratio as of Apr 24 2024 is 26.1.
More Details
Regeneron Pharmaceuticals Inc (BSP:REGN34) PE Ratio (TTM) Chart
Regeneron Pharmaceuticals Inc (BSP:REGN34) PE Ratio (TTM) Historical Data
View and export this data going back to 2019. Start your Free Trial
Total 1257
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Regeneron Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-25 | 27.3 | 2024-02-20 | 27.1 |
| 2024-04-23 | 27.3 | 2024-02-19 | 27.5 |
| 2024-04-22 | 27.3 | 2024-02-16 | 27.5 |
| 2024-04-19 | 27.4 | 2024-02-15 | 27.6 |
| 2024-04-18 | 27.4 | 2024-02-14 | 27.0 |
| 2024-04-17 | 27.2 | 2024-02-13 | 27.4 |
| 2024-04-16 | 27.2 | 2024-02-12 | 27.4 |
| 2024-04-15 | 27.0 | 2024-02-09 | 27.4 |
| 2024-04-12 | 27.0 | 2024-02-08 | 27.3 |
| 2024-04-11 | 27.4 | 2024-02-07 | 27.4 |
| 2024-04-10 | 27.4 | 2024-02-06 | 26.8 |
| 2024-04-09 | 27.3 | 2024-02-05 | 27.7 |
| 2024-04-08 | 27.4 | 2024-02-02 | 27.7 |
| 2024-04-05 | 27.8 | 2024-02-01 | 27.1 |
| 2024-04-04 | 28.0 | 2024-01-31 | 27.6 |
| 2024-04-03 | 28.0 | 2024-01-30 | 27.1 |
| 2024-04-02 | 28.0 | 2024-01-29 | 27.1 |
| 2024-04-01 | 27.8 | 2024-01-26 | 26.8 |
| 2024-03-28 | 27.8 | 2024-01-25 | 27.1 |
| 2024-03-27 | 27.8 | 2024-01-24 | 27.1 |
| 2024-03-26 | 27.8 | 2024-01-23 | 26.6 |
| 2024-03-25 | 28.1 | 2024-01-22 | 26.6 |
| 2024-03-22 | 28.1 | 2024-01-19 | 26.6 |
| 2024-03-21 | 28.1 | 2024-01-18 | 25.9 |
| 2024-03-20 | 28.0 | 2024-01-17 | 25.9 |
| 2024-03-19 | 28.0 | 2024-01-16 | 25.9 |
| 2024-03-18 | 27.4 | 2024-01-15 | 25.9 |
| 2024-03-15 | 27.4 | 2024-01-12 | 25.9 |
| 2024-03-14 | 27.4 | 2024-01-11 | 25.9 |
| 2024-03-13 | 27.7 | 2024-01-10 | 25.4 |
| 2024-03-12 | 27.7 | 2024-01-09 | 25.4 |
| 2024-03-11 | 27.7 | 2024-01-08 | 25.2 |
| 2024-03-08 | 27.9 | 2024-01-05 | 26.0 |
| 2024-03-07 | 27.9 | 2024-01-04 | 25.9 |
| 2024-03-06 | 27.9 | 2024-01-03 | 25.9 |
| 2024-03-05 | 27.9 | 2024-01-02 | 25.5 |
| 2024-03-04 | 27.9 | 2024-01-01 | 23.7 |
| 2024-03-01 | 28.3 | 2023-12-29 | 23.7 |
| 2024-02-29 | 28.1 | 2023-12-28 | 23.7 |
| 2024-02-28 | 28.4 | 2023-12-27 | 23.0 |
| 2024-02-27 | 28.4 | 2023-12-26 | 23.0 |
| 2024-02-26 | 28.4 | 2023-12-25 | 23.2 |
| 2024-02-23 | 27.4 | 2023-12-22 | 23.2 |
| 2024-02-22 | 27.4 | 2023-12-21 | 23.2 |
| 2024-02-21 | 27.1 | 2023-12-20 | 23.2 |
Regeneron Pharmaceuticals Inc (BSP:REGN34) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Regeneron Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : BRREGNBDR005
Share Class Description:
BSP:REGN34: ADRCompare
Compare
Traded in other countries / regions
REGN.USAREGN34.BrazilREGN.MexicoRGO.GermanyREGN.Austria1REGN.Italy0R2M.UK IPO Date
2019-04-29Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers